Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Notes Payables (2017 - 2019)

Anaptysbio's Notes Payables history spans 3 years, with the latest figure at $1.4 million for Q4 2019.

  • For Q4 2019, Notes Payables fell 81.85% year-over-year to $1.4 million; the TTM value through Dec 2019 reached $1.4 million, down 81.85%, while the annual FY2019 figure was $1.4 million, 81.85% down from the prior year.
  • Notes Payables reached $1.4 million in Q4 2019 per ANAB's latest filing, down from $3.1 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $7.6 million in Q4 2018 to a low of $1.2 million in Q1 2017.
  • Average Notes Payables over 3 years is $5.2 million, with a median of $5.7 million recorded in 2017.
  • Peak YoY movement for Notes Payables: skyrocketed 500.0% in 2018, then tumbled 81.85% in 2019.
  • A 3-year view of Notes Payables shows it stood at $6.9 million in 2017, then rose by 10.17% to $7.6 million in 2018, then plummeted by 81.85% to $1.4 million in 2019.
  • Per Business Quant, the three most recent readings for ANAB's Notes Payables are $1.4 million (Q4 2019), $3.1 million (Q3 2019), and $4.8 million (Q2 2019).